Quick Answer
Alaunos Therapeutics, Inc. reported Stockholders Equity of $2.15 million for the year ending 2025.
- Alaunos Therapeutics, Inc. showed an increase of +4.4% in Stockholders Equity from 2024 to 2025.
- This data is from Alaunos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2011: $71.61 million | Q1 2012: $97.70 million | Q3 2012: $59.03 million | Q1 2013: $37.89 million | Q2 2013: $19.33 million | Q3 2013: $3.63 million | Q1 2014: $41.73 million | Q2 2014: $37.72 million | Q3 2014: $36.48 million | Q1 2015: $120.60 million | Q2 2015: $110.44 million | Q3 2015: $93.84 million | Q1 2016: $77.81 million | Q2 2016: -$51.99 million | Q3 2016: -$64.42 million | Q1 2017: -$94.90 million | Q2 2017: -$64.27 million | Q3 2017: -$79.80 million | Q1 2018: -$123.15 million | Q2 2018: -$139.24 million | Q3 2018: -$156.41 million | Q1 2019: $74.22 million | Q2 2019: $62.00 million | Q3 2019: $106.13 million | Q1 2020: $180.34 million | Q2 2020: $163.41 million | Q3 2020: $144.92 million | Q1 2021: $105.64 million | Q2 2021: $88.28 million | Q3 2021: $68.71 million | Q1 2022: $49.12 million | Q2 2022: $40.18 million | Q3 2022: $32.11 million | Q1 2023: $29.51 million | Q2 2023: $21.65 million | Q3 2023: $13.90 million | Q1 2024: $4.80 million | Q2 2024: $3.77 million | Q3 2024: $2.72 million | Q1 2025: $1.06 million | Q2 2025: $3.66 million | Q3 2025: $2.80 million.
- Over the full 16 years of available data (2010 to 2025), Alaunos Therapeutics, Inc.'s Stockholders Equity has declined by 93.0%.
- Historical annual values: Fiscal year 2025: $2.15 million | Fiscal year 2024: $2.06 million | Fiscal year 2023: $6.31 million | Fiscal year 2022: $38.56 million | Fiscal year 2021: $58.06 million | Fiscal year 2020: $123.98 million | Fiscal year 2019: $95.01 million | Fiscal year 2018: $85.56 million | Fiscal year 2017: -$96.81 million | Fiscal year 2016: -$77.30 million | Fiscal year 2015: $87.37 million | Fiscal year 2014: $33.84 million | Fiscal year 2013: $49.38 million | Fiscal year 2012: $48.45 million | Fiscal year 2011: $71.61 million | Fiscal year 2010: $30.55 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: